Lillian Pinault
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lillian Pinault has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Elias K. Spanakis
Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publications Guillermo E. Umpierrez
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
2 shared publicationsJohn D. Sorkin
Baltimore Veterans Affairs Medical Center GRECC (Geriatric Research, Education, and Clinical Center), MD, USA
2 shared publicationsLakshmi G. Singh
Division of Diabetes and Endocrinology, Baltimore Veterans Affairs Medical Center, MD, USA
2 shared publicationsMedha Satyarengga
Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publicationsMin Zhan
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publications
Latest Publications
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 20
Hyperinsulinemic hypoglycemia, clinical considerations and a case report of a novel GCK mutation
- 1 June 2021
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 20
Open AccessHyperinsulinemic hypoglycemia, clinical considerations and a case report of a novel GCK mutation
- Open Access
goFOODTM: An Artificial Intelligence System for Dietary Assessment
Accurate estimation of nutritional information may lead to healthier diets and better clinical outcomes. We propose a dietary assessment system based on artificial intelligence (AI), named goFOODTM. The system can estimate the calorie and macronutrient content of a meal, on the sole basis of food images captured by a smartphone. goFOODTM requires an input of two meal images or a short video. For conventional single-camera smartphones, the images must be captured from two different viewing angles; smartphones equipped with two rear cameras require only a single press of the shutter button. The deep neural networks are used to process the two images and implements food detection, segmentation and recognition, while a 3D reconstruction algorithm estimates the food’s volume. Each meal’s calorie and macronutrient content is calculated from the food category, volume and the nutrient database. goFOODTM supports 319 fine-grained food categories, and has been validated on two multimedia databases that contain non-standardized and fast food meals. The experimental results demonstrate that goFOODTM performed better than experienced dietitians on the non-standardized meal database, and was comparable to them on the fast food database. goFOODTM provides a simple and efficient solution to the end-user for dietary assessment.
Open AccessgoFOODTM: An Artificial Intelligence System for Dietary Assessment
Accurate estimation of nutritional information may lead to healthier diets and better clinical outcomes. We propose a dietary assessment system based on artificial intelligence (AI), named goFOODTM. The system can estimate the calorie and macronutrient content of a meal, on the sole basis of food images captured by a smartphone. goFOODTM requires an input of two meal images or a short video. For conventional single-camera smartphones, the images must be captured from two different viewing angles; smartphones equipped with two rear cameras require only a single press of the shutter button. The deep neural networks are used to process the two images and implements food detection, segmentation and recognition, while a 3D reconstruction algorithm estimates the food’s volume. Each meal’s calorie and macronutrient content is calculated from the food category, volume and the nutrient database. goFOODTM supports 319 fine-grained food categories, and has been validated on two multimedia databases that contain non-standardized and fast food meals. The experimental results demonstrate that goFOODTM performed better than experienced dietitians on the non-standardized meal database, and was comparable to them on the fast food database. goFOODTM provides a simple and efficient solution to the end-user for dietary assessment.
- Open Access
- 28 November 2019
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 14 (4) , 783-790
Continuous Glucose Monitoring in General Wards for Prevention of Hypoglycemia: Results From the Glucose Telemetry System Pilot Study
Limited evidence is available about the use of continuous glucose monitoring (CGM) in general wards. In this pilot study we evaluated the use of the glucose telemetry system (GTS) using CGM technology and remote monitoring to prevent inpatient hypoglycemia in high-risk insulin-treated patients with type 2 diabetes (DM2). A prospective, single-center, randomized pilot study was conducted to determine whether GTS can prevent inpatient hypoglycemia. Patients were randomized to standard of care with point-of-care glucose testing or to the intervention group with GTS. Both groups used CGM (blinded vs real time). Our primary goal was prevention of inpatient hypoglycemia. A total of 13 subjects completed the study: 7 in the standard of care and 6 in the intervention group. The hypoglycemia event rate was 0.20 ± 0.23 episodes/day in standard of care vs 0.07 ± 0.11 episodes/day in the intervention group (P = .31). Six hypoglycemic events occurred in the standard of care vs two in the intervention group. Percentage of time spent <70 mg/dL was 2.44% ± 3.86% vs 0.30% ± 0.39% (P = .54) and time spent <54 mg/dL was 0.29% ± 0.47% vs 0% (P = .19) in the standard-of-care and intervention groups, respectively. Utilizing GTS for DM2 insulin-treated patients in the general wards may be beneficial in reducing hypoglycemia. Based on the results of our pilot study we have initiated a large-scale randomized-controlled trial to further evaluate GTS in the general wards in patients with DM2 at high risk for inpatient hypoglycemia.
- 28 November 2019
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 14 (4) , 783-790
Open AccessContinuous Glucose Monitoring in General Wards for Prevention of Hypoglycemia: Results From the Glucose Telemetry System Pilot Study
Limited evidence is available about the use of continuous glucose monitoring (CGM) in general wards. In this pilot study we evaluated the use of the glucose telemetry system (GTS) using CGM technology and remote monitoring to prevent inpatient hypoglycemia in high-risk insulin-treated patients with type 2 diabetes (DM2). A prospective, single-center, randomized pilot study was conducted to determine whether GTS can prevent inpatient hypoglycemia. Patients were randomized to standard of care with point-of-care glucose testing or to the intervention group with GTS. Both groups used CGM (blinded vs real time). Our primary goal was prevention of inpatient hypoglycemia. A total of 13 subjects completed the study: 7 in the standard of care and 6 in the intervention group. The hypoglycemia event rate was 0.20 ± 0.23 episodes/day in standard of care vs 0.07 ± 0.11 episodes/day in the intervention group (P = .31). Six hypoglycemic events occurred in the standard of care vs two in the intervention group. Percentage of time spent <70 mg/dL was 2.44% ± 3.86% vs 0.30% ± 0.39% (P = .54) and time spent <54 mg/dL was 0.29% ± 0.47% vs 0% (P = .19) in the standard-of-care and intervention groups, respectively. Utilizing GTS for DM2 insulin-treated patients in the general wards may be beneficial in reducing hypoglycemia. Based on the results of our pilot study we have initiated a large-scale randomized-controlled trial to further evaluate GTS in the general wards in patients with DM2 at high risk for inpatient hypoglycemia.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
1246-P: Reducing Hypoglycemia in the Noncritical Care Setting Using CGM Devices: The Glucose Telemetry System
Objective: In a pilot study we have previously demonstrated successful transmission of glucometric values from continuous glucose monitoring (CGM) devices to a monitoring system at the nursing station (Glucose Telemetry System-GTS). In an ongoing study, we are evaluating whether use of GTS can reduce inpatient hypoglycemia compared to point of care (POC) capillary glucose testing, without increasing hyperglycemia. Design: Twenty-four patients with DM2 at high risk for inpatient hypoglycemia were randomized to GTS (N=12 intervention group) or POC (N=12 standard of care). Nursing staff were asked to proceed with hypoglycemia preventative actions for GTS low glucose alarms set at <85 mg/dL. Subjects randomized to standard of care used “blinded” CGM. Mean percent time spent in hypoglycemia, hyperglycemia, and hypoglycemia event rates were evaluated. Results: Twenty-one subjects were included in the analysis, 2 subjects withdrew due to minor bleeding at CGM insertion site and 1 subject had insufficient CGM data due to sensor failure. 30 GTS hypoglycemia alarms occurred in 7 different subjects. Overall percent time spent in hypoglycemia (≤70 mg/dL) was 0.18%±0.21 versus 1.64%±1.59 (p=0.056), and clinically significant hypoglycemia (<54mg/dL) was 0.01%±0.01 versus 0.48%±1.07 (p=0.135), between intervention and control groups, respectively. Rate of hypoglycemic episodes per day/per patient was 0.12±0.17 vs. 0.27±0.33 (p=0.19) for GTS and POC, respectively. Percent time spent in normoglycemia (70-179 mg/dL) was 52.04%±23.65 versus 52.92%±27.37 (p=0.94), while percent time in hyperglycemia (≥180 mg/dL) was 47.80%±23.65 versus 45.43%±28.05 (p=0.84), respectively. Conclusion: In this preliminary analysis, subjects monitored by GTS had a non-statistically significant decrease in inpatient hypoglycemia compared to standard of care. Disclosure: E. Spanakis: None. M. Satyarengga: None. L.G. Singh: None. L. Pinault: None. J.D. Sorkin: None. M. Zhan: None. G.E. Umpierrez: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; AstraZeneca, Merck & Co., Inc., Novo Nordisk Inc., Sanofi US. Funding: U.S. Department of Veterans Affairs (1I01CX001825-01)
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
1246-P: Reducing Hypoglycemia in the Noncritical Care Setting Using CGM Devices: The Glucose Telemetry System
Objective: In a pilot study we have previously demonstrated successful transmission of glucometric values from continuous glucose monitoring (CGM) devices to a monitoring system at the nursing station (Glucose Telemetry System-GTS). In an ongoing study, we are evaluating whether use of GTS can reduce inpatient hypoglycemia compared to point of care (POC) capillary glucose testing, without increasing hyperglycemia. Design: Twenty-four patients with DM2 at high risk for inpatient hypoglycemia were randomized to GTS (N=12 intervention group) or POC (N=12 standard of care). Nursing staff were asked to proceed with hypoglycemia preventative actions for GTS low glucose alarms set at <85 mg/dL. Subjects randomized to standard of care used “blinded” CGM. Mean percent time spent in hypoglycemia, hyperglycemia, and hypoglycemia event rates were evaluated. Results: Twenty-one subjects were included in the analysis, 2 subjects withdrew due to minor bleeding at CGM insertion site and 1 subject had insufficient CGM data due to sensor failure. 30 GTS hypoglycemia alarms occurred in 7 different subjects. Overall percent time spent in hypoglycemia (≤70 mg/dL) was 0.18%±0.21 versus 1.64%±1.59 (p=0.056), and clinically significant hypoglycemia (<54mg/dL) was 0.01%±0.01 versus 0.48%±1.07 (p=0.135), between intervention and control groups, respectively. Rate of hypoglycemic episodes per day/per patient was 0.12±0.17 vs. 0.27±0.33 (p=0.19) for GTS and POC, respectively. Percent time spent in normoglycemia (70-179 mg/dL) was 52.04%±23.65 versus 52.92%±27.37 (p=0.94), while percent time in hyperglycemia (≥180 mg/dL) was 47.80%±23.65 versus 45.43%±28.05 (p=0.84), respectively. Conclusion: In this preliminary analysis, subjects monitored by GTS had a non-statistically significant decrease in inpatient hypoglycemia compared to standard of care. Disclosure: E. Spanakis: None. M. Satyarengga: None. L.G. Singh: None. L. Pinault: None. J.D. Sorkin: None. M. Zhan: None. G.E. Umpierrez: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; AstraZeneca, Merck & Co., Inc., Novo Nordisk Inc., Sanofi US. Funding: U.S. Department of Veterans Affairs (1I01CX001825-01)
- Open Access
- 26 July 2017
- Published by Springer Nature in Implementation Science
- Vol. 12 (1) , 1-14
Implementation findings from a hybrid III implementation-effectiveness trial of the Diabetes Prevention Program (DPP) in the Veterans Health Administration (VHA)
The Diabetes Prevention Program (DPP) is an effective lifestyle intervention to reduce incidence of type 2 diabetes. However, there are gaps in knowledge about how to implement DPP. The aim of this study was to evaluate implementation of DPP via assessment of a clinical demonstration in the Veterans Health Administration (VHA). A 12-month pragmatic clinical trial compared weight outcomes between the Veterans Affairs Diabetes Prevention Program (VA-DPP) and the usual care MOVE!® weight management program (MOVE!). Eligible participants had a body mass index (BMI) ≥30 kg/m2 (or BMI ≥ 25 kg/m2 with one obesity-related condition), prediabetes (glycosylated hemoglobin (HbA1c) 5.7–6.5% or fasting plasma glucose (FPG) 100–125 mg/dL), lived within 60 min of their VA site, and had not participated in a weight management program within the last year. Established evaluation and implementation frameworks were used to guide the implementation evaluation. Implementation barriers and facilitators, delivery fidelity, participant satisfaction, and implementation costs were assessed. Using micro-costing methods, costs for assessment of eligibility and scheduling and maintaining adherence per participant, as well as cost of delivery per session, were also assessed. Several barriers and facilitators to Reach, Adoption, Implementation, Effectiveness and Maintenance were identified; barriers related to Reach were the largest challenge encountered by site teams. Fidelity was higher for VA-DPP delivery compared to MOVE! for five of seven domains assessed. Participant satisfaction was high in both programs, but higher in VA-DPP for most items. Based on micro-costing methods, cost of assessment for eligibility was $68/individual assessed, cost of scheduling and maintaining adherence was $328/participant, and cost of delivery was $101/session. Multi-faceted strategies are needed to reach targeted participants and successfully implement DPP. Costs for assessing patients for eligibility need to be carefully considered while still maximizing reach to the targeted population.
- 26 July 2017
- Published by Springer Nature in Implementation Science
- Vol. 12 (1) , 1-14
Open AccessImplementation findings from a hybrid III implementation-effectiveness trial of the Diabetes Prevention Program (DPP) in the Veterans Health Administration (VHA)
The Diabetes Prevention Program (DPP) is an effective lifestyle intervention to reduce incidence of type 2 diabetes. However, there are gaps in knowledge about how to implement DPP. The aim of this study was to evaluate implementation of DPP via assessment of a clinical demonstration in the Veterans Health Administration (VHA). A 12-month pragmatic clinical trial compared weight outcomes between the Veterans Affairs Diabetes Prevention Program (VA-DPP) and the usual care MOVE!® weight management program (MOVE!). Eligible participants had a body mass index (BMI) ≥30 kg/m2 (or BMI ≥ 25 kg/m2 with one obesity-related condition), prediabetes (glycosylated hemoglobin (HbA1c) 5.7–6.5% or fasting plasma glucose (FPG) 100–125 mg/dL), lived within 60 min of their VA site, and had not participated in a weight management program within the last year. Established evaluation and implementation frameworks were used to guide the implementation evaluation. Implementation barriers and facilitators, delivery fidelity, participant satisfaction, and implementation costs were assessed. Using micro-costing methods, costs for assessment of eligibility and scheduling and maintaining adherence per participant, as well as cost of delivery per session, were also assessed. Several barriers and facilitators to Reach, Adoption, Implementation, Effectiveness and Maintenance were identified; barriers related to Reach were the largest challenge encountered by site teams. Fidelity was higher for VA-DPP delivery compared to MOVE! for five of seven domains assessed. Participant satisfaction was high in both programs, but higher in VA-DPP for most items. Based on micro-costing methods, cost of assessment for eligibility was $68/individual assessed, cost of scheduling and maintaining adherence was $328/participant, and cost of delivery was $101/session. Multi-faceted strategies are needed to reach targeted participants and successfully implement DPP. Costs for assessing patients for eligibility need to be carefully considered while still maximizing reach to the targeted population.